Fulgent Genetics (FLGT) Research & Development (2015 - 2026)

Fulgent Genetics has disclosed Research & Development across 12 years of filings, most recently posting $15.2 million for Q2 2026.

• In Q2 2026, Research & Development rose 12.97% year-over-year to $15.2 million; the TTM figure through Jun 2026 stood at $57.4 million (up 15.4% YoY), while the FY2025 annual figure was $53.9 million, up 10.42% from the prior year.
• Research & Development came in at $15.2 million for Q2 2026 at Fulgent Genetics, up from $14.2 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $15.2 million in Q2 2026 to a low of $7.9 million in Q1 2022.
• Average Research & Development over 5 years is $11.8 million, with a median of $11.6 million recorded in 2024.
• Year-over-year, Research & Development surged 104.56% in 2022 and retreated 1.32% in 2023.
• Over 5 years, Research & Development stood at $10.3 million in 2022, then advanced by 2.41% to $10.5 million in 2023, then gained by 15.36% to $12.1 million in 2024, then rose by 16.98% to $14.2 million in 2025, then climbed by 7.47% to $15.2 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $15.2 million in Q2 2026, $14.2 million in Q1 2026, and $14.2 million in Q4 2025.